The use of levetiracetam in refractory status epilepticus

Nitin C. Patel, Ivan R. Landan, Jeffrey Levin, Jerzy Szaflarski, Andrew Wilner

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Six patients with status epilepticus (SE) of various etiologies refractory to at least two antiepileptic drugs (AEDs) had complete cessation of their seizures following administration of oral levetiracetam (LEV). Seizure types included convulsive, focal, and nonconvulsive status epilepticus. Effective doses of levetiracetam ranged from 500 to 3000 mg/day, achieving seizure control within 12-96 h. No significant adverse events were noted. Adjunctive levetiracetam should be considered for patients with status epilepticus unresponsive to initial therapy.

Original languageEnglish (US)
Pages (from-to)137-141
Number of pages5
JournalSeizure
Volume15
Issue number3
DOIs
StatePublished - Apr 1 2006

Fingerprint

etiracetam
Status Epilepticus
Seizures
Anticonvulsants
Oral Administration

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

Patel, N. C., Landan, I. R., Levin, J., Szaflarski, J., & Wilner, A. (2006). The use of levetiracetam in refractory status epilepticus. Seizure, 15(3), 137-141. https://doi.org/10.1016/j.seizure.2005.12.003

The use of levetiracetam in refractory status epilepticus. / Patel, Nitin C.; Landan, Ivan R.; Levin, Jeffrey; Szaflarski, Jerzy; Wilner, Andrew.

In: Seizure, Vol. 15, No. 3, 01.04.2006, p. 137-141.

Research output: Contribution to journalArticle

Patel, NC, Landan, IR, Levin, J, Szaflarski, J & Wilner, A 2006, 'The use of levetiracetam in refractory status epilepticus', Seizure, vol. 15, no. 3, pp. 137-141. https://doi.org/10.1016/j.seizure.2005.12.003
Patel, Nitin C. ; Landan, Ivan R. ; Levin, Jeffrey ; Szaflarski, Jerzy ; Wilner, Andrew. / The use of levetiracetam in refractory status epilepticus. In: Seizure. 2006 ; Vol. 15, No. 3. pp. 137-141.
@article{046a1e711d834adc810bb80347657297,
title = "The use of levetiracetam in refractory status epilepticus",
abstract = "Six patients with status epilepticus (SE) of various etiologies refractory to at least two antiepileptic drugs (AEDs) had complete cessation of their seizures following administration of oral levetiracetam (LEV). Seizure types included convulsive, focal, and nonconvulsive status epilepticus. Effective doses of levetiracetam ranged from 500 to 3000 mg/day, achieving seizure control within 12-96 h. No significant adverse events were noted. Adjunctive levetiracetam should be considered for patients with status epilepticus unresponsive to initial therapy.",
author = "Patel, {Nitin C.} and Landan, {Ivan R.} and Jeffrey Levin and Jerzy Szaflarski and Andrew Wilner",
year = "2006",
month = "4",
day = "1",
doi = "10.1016/j.seizure.2005.12.003",
language = "English (US)",
volume = "15",
pages = "137--141",
journal = "Seizure : the journal of the British Epilepsy Association",
issn = "1059-1311",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - The use of levetiracetam in refractory status epilepticus

AU - Patel, Nitin C.

AU - Landan, Ivan R.

AU - Levin, Jeffrey

AU - Szaflarski, Jerzy

AU - Wilner, Andrew

PY - 2006/4/1

Y1 - 2006/4/1

N2 - Six patients with status epilepticus (SE) of various etiologies refractory to at least two antiepileptic drugs (AEDs) had complete cessation of their seizures following administration of oral levetiracetam (LEV). Seizure types included convulsive, focal, and nonconvulsive status epilepticus. Effective doses of levetiracetam ranged from 500 to 3000 mg/day, achieving seizure control within 12-96 h. No significant adverse events were noted. Adjunctive levetiracetam should be considered for patients with status epilepticus unresponsive to initial therapy.

AB - Six patients with status epilepticus (SE) of various etiologies refractory to at least two antiepileptic drugs (AEDs) had complete cessation of their seizures following administration of oral levetiracetam (LEV). Seizure types included convulsive, focal, and nonconvulsive status epilepticus. Effective doses of levetiracetam ranged from 500 to 3000 mg/day, achieving seizure control within 12-96 h. No significant adverse events were noted. Adjunctive levetiracetam should be considered for patients with status epilepticus unresponsive to initial therapy.

UR - http://www.scopus.com/inward/record.url?scp=33645024140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645024140&partnerID=8YFLogxK

U2 - 10.1016/j.seizure.2005.12.003

DO - 10.1016/j.seizure.2005.12.003

M3 - Article

VL - 15

SP - 137

EP - 141

JO - Seizure : the journal of the British Epilepsy Association

JF - Seizure : the journal of the British Epilepsy Association

SN - 1059-1311

IS - 3

ER -